Document Detail


Cholesterol reduction yields clinical benefits: meta-analysis including recent trials.
MedLine Citation:
PMID:  17697899     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Previous meta-analyses reported by Gould et al found significant decreases of 15% in the risk for coronary heart disease (CHD)-related mortality and 11 % in risk for all-cause mortality per decrease of 10% in total cholesterol (TC) level. OBJECTIVE: To evaluate the effects of reducing cholesterol on clinical events after including data from recent clinical trials. METHODS: Using a literature search (MeSH key terms, including: bezafibrate, coronary disease, efficacy, gemfibrozil, hydroxymethylglutaryl-CoA reductase inhibitors, hypercholesterolemia, niacin [nicotinic acids], randomized controlled trials, and treatment outcome; years: 1999-2005), we identified trials published in English that assessed the effects of lipid-modifying therapies on CHD end points, including CHD-related death, myocardial infarction, and angina pectoris. We also included all studies from the previously published meta-analysis. Using the same analytic approach as previously, we determined the effects of net absolute reductions (1 mmol/L [38.7 mg/dL]) in TC and low-density lipoprotein cholesterol (LDL-C) on the relative risks (RRs) for all-cause mortality, CHD-related mortality, any CHD event (mortality or nonfatal myocardial infarction), and non-CHD-related mortality. RESULTS: We included 62 studies involving 216,616 patients, including 126,474 from 24 randomized controlled trials the findings of which were published since the previous meta-analysis (1998). Among all patients, for every 1-mmol/L decrease in TC, there was a 17.5 reduction in RR for all-cause mortality; 24.5 %, for CHD-related mortality; and 29.5% for any CHD event. Corresponding reductions for every 1-mmol/L decrease in LDL-C were 15.6%, 28.0%, and 26.6%, respectively. Similar relationships were observed in patients without CHD. No significant relationship was found between lipid reduction and non-CHD-related mortality risk. CONCLUSIONS: The results from the present analysis support conclusions from previous meta-analyses that cholesterol lowering is clinically beneficial in patients with CHD or at elevated CHD risk. These results also support the previous finding that non-CHD-related mortality is unrelated to lipid reductions.
Authors:
A Lawrence Gould; Glenn M Davies; Evo Alemao; Donald D Yin; John R Cook
Related Documents :
11575709 - A clinical focus on statins.
9329379 - Both hypothyroidism and hyperthyroidism enhance low density lipoprotein oxidation.
12423319 - High oxidized ldl and elevated plasma homocysteine contribute to the early reduction of...
1751679 - Ldl-apheresis and improvement in the coronary atherosclerosis of familial hypercholeste...
24217829 - A less aggressive therapeutic option for electrical storm.
19114199 - Effect of preoperative statins in patients without coronary artery disease who undergo ...
9554809 - Diminished responsiveness of gs-coupled receptors in severely failing human hearts: no ...
9533999 - Seeing objects smaller than they are: micropsia following right temporo-parietal infarc...
21675829 - Phaeochromocytoma in a 86-year-old patient presenting with reversible myocardial dysfun...
Publication Detail:
Type:  Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Clinical therapeutics     Volume:  29     ISSN:  0149-2918     ISO Abbreviation:  Clin Ther     Publication Date:  2007 May 
Date Detail:
Created Date:  2007-08-16     Completed Date:  2007-09-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7706726     Medline TA:  Clin Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  778-94     Citation Subset:  IM    
Affiliation:
Merck Research Laboratories, West Point, PA 19486, USA. goulda@merck.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticholesteremic Agents / therapeutic use*
Cholesterol / blood
Cholesterol, LDL / blood
Coronary Disease / epidemiology,  mortality,  prevention & control*
Humans
Myocardial Infarction / epidemiology,  prevention & control
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Cholesterol, LDL; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hypertriglyceridemia and cardiovascular risk reduction.
Next Document:  Inhaled dry powder insulin for the treatment of diabetes mellitus.